Study guide
5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy
ABIM Internal Medicine Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 0: The ABIM Exam, Blueprint & Study Strategy
0.1 Exam Format, Question Types & the 2026 Blueprint 0.2 Eligibility, Registration, Fees & Exam-Day Logistics 0.3 Scoring, the Passing Standard & Score Reports 0.4 Building a Blueprint-Weighted Study Plan
2 Chapter 1: Cardiovascular Disease (14% of Exam)
1.1 Ischemic Heart Disease & Acute Coronary Syndromes 1.2 Antithrombotic Therapy, Secondary Prevention & Mechanical Complications of MI 1.3 Atrial Fibrillation, Atrial Flutter & Stroke Prevention 1.4 Supraventricular Tachycardias, Ventricular Arrhythmias & Bradycardias 1.5 Heart Failure: Classification, Staging & Guideline-Directed Medical Therapy 1.6 Device Therapy, HFpEF & the Cardiomyopathies 1.7 Valvular Heart Disease & Endocarditis Prophylaxis 1.8 Pericardial Disease & Acute Aortic Syndromes 1.9 Hypertension: Classification, Diagnosis & Secondary Causes 1.10 Hypertensive Crises & Dyslipidemia 1.11 Adult Congenital Heart Disease & Coarctation of the Aorta 1.12 Syncope: Reflex, Orthostatic & Cardiac Causes 1.13 Cardiac Physical Examination, Murmurs & Antithrombotic Selection
3 Chapter 2: Endocrinology, Diabetes & Metabolism (9% of Exam)
2.1 Diabetes Mellitus: Diagnosis, Glycemic Targets & Pharmacotherapy 2.2 Insulin Therapy, Hyperglycemic Emergencies & Chronic Complications 2.3 Thyroid Function Testing & Hypothyroidism 2.4 Thyrotoxicosis, Thyroid Storm & Thyroid Nodules 2.5 Adrenal & Pituitary Disorders 2.6 Hypercalcemia, Hypocalcemia & Disorders of Mineral Metabolism 2.7 Osteoporosis & Paget Disease of Bone 2.8 Ovarian, Testicular & Reproductive Endocrine Disorders 2.9 Hypoglycemia, Endocrine Tumors, Polyglandular Syndromes & Severe Hypertriglyceridemia
4 Chapter 3: Gastroenterology & Hepatology (9% of Exam)
3.1 Esophageal Disease 3.2 Stomach & Duodenal Disease and Gastrointestinal Hemorrhage 3.3 Inflammatory Bowel Disease 3.4 Celiac Disease & Irritable Bowel Syndrome 3.5 Diverticular Disease & Colorectal Cancer Screening 3.6 Viral Hepatitis, Steatotic & Alcohol-Associated Liver Disease 3.7 Cirrhosis & the Complications of Portal Hypertension 3.8 Acute Pancreatitis 3.9 Chronic Pancreatitis & Biliary Tract Disease 3.10 Inherited, Autoimmune & Drug-Induced Liver Disease 3.11 Small Intestinal Disease, Ischemia & Gastrointestinal Complications of HIV
5 Chapter 4: Infectious Disease (9% of Exam)
4.1 Lower Respiratory Tract Infections & Sepsis Syndromes 4.2 Viral Respiratory Pathogens & Tuberculosis 4.3 Central Nervous System Infections 4.4 Skin, Soft Tissue, Bone & Joint Infections 4.5 Infective Endocarditis & Cardiovascular Infection 4.6 Clostridioides difficile & Catheter-Related Bloodstream Infection 4.7 HIV Diagnosis, Antiretroviral Therapy & Prevention 4.8 Opportunistic Infections & Sexually Transmitted Infections 4.9 Fever of Unknown Origin, Neutropenic Fever & Toxic Shock 4.10 Travel-Related Illness, Vector-Borne Disease & Outbreaks 4.11 Infection Prevention, Nosocomial Infection & Postexposure Prophylaxis 4.12 Rheumatic Fever, Poststreptococcal Disease, Enteric & Hepatic Infections
6 Chapter 5: Pulmonary Disease (9% of Exam)
5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy 5.2 Interventions That Reduce COPD Mortality & Exacerbation Management 5.3 Asthma: Diagnosis, Stepwise Therapy & Status Asthmaticus 5.4 Interstitial Lung Disease & Idiopathic Pulmonary Fibrosis 5.5 Sarcoidosis, Hypersensitivity Pneumonitis & Occupational Lung Disease 5.6 Pulmonary Embolism: Diagnosis, Risk Stratification & Anticoagulation 5.7 Pulmonary Hypertension & Sleep-Disordered Breathing 5.8 Acute Respiratory Distress Syndrome & Mechanical Ventilation 5.9 Pleural Disease, Empyema & Pneumothorax 5.10 Bronchiectasis, Cystic Fibrosis & Restrictive Lung Disease 5.11 Evaluation of Cough, Dyspnea, Hemoptysis & the Solitary Pulmonary Nodule
7 Chapter 6: Rheumatology & Orthopedics (9% of Exam)
6.1 Rheumatoid Arthritis: Diagnosis & Systemic Manifestations 6.2 Antirheumatic Pharmacotherapy & the Spondyloarthropathies 6.3 Gout: Pathophysiology & Acute Management 6.4 Urate-Lowering Therapy & Calcium Pyrophosphate Deposition Disease 6.5 Osteoarthritis 6.6 Systemic Lupus Erythematosus 6.7 Systemic Sclerosis, Sjogren Syndrome & Inflammatory Myopathies 6.8 The Vasculitides 6.9 Regional Musculoskeletal Syndromes, Back Pain & Sports Injuries 6.10 Other Primary Rheumatic Disorders & Mixed Connective Tissue Disease 6.11 Osteonecrosis & Metabolic Bone Disease
8 Chapter 7: Hematology (6% of Exam)
7.1 Approach to Anemia & the Microcytic Anemias 7.2 Macrocytic, Normocytic & Hemolytic Anemias 7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria 7.4 Platelet Disorders, Thrombocytopenia & the Bleeding Patient 7.5 Coagulation Factor Disorders, Thrombophilia & Anticoagulant Reversal 7.6 Acute Leukemias, Chronic Leukemias & Myeloproliferative Neoplasms 7.7 Lymphomas & Plasma Cell Disorders 7.8 Myelodysplastic Syndrome, Myeloproliferative Neoplasms & Porphyria 7.9 Transfusion Medicine & Late Complications of Transplantation
9 Chapter 8: Medical Oncology (6% of Exam)
8.1 Breast, Lung, Colorectal & Prostate Cancer 8.2 Oncologic Emergencies 8.3 Genitourinary & Gynecologic Malignancies 8.4 Head and Neck, Bone & Soft Tissue Cancer and Cancer of Unknown Primary 8.5 Complications of Cancer & Its Treatment 8.6 Cancer Prevention, Survivorship & Psychosocial Care
10 Chapter 9: Nephrology & Urology (6% of Exam)
9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy 9.2 Glomerular Disorders & Nephrotic Syndrome 9.3 Nephritic Syndromes, RPGN & Indications for Renal Replacement Therapy 9.4 Chronic Kidney Disease: Staging & Progression Retardation 9.5 Complications of Chronic Kidney Disease: Anemia, CKD-MBD & Acidosis 9.6 Hyponatremia, Hypernatremia & Water Balance 9.7 Potassium Disorders & Systematic Acid-Base Analysis 9.8 Renal Tubular Acidosis & Nephrolithiasis 9.9 Prostate Disorders, Urinary Incontinence & Other Urologic Conditions 9.10 Cystic Kidney Disease, Obstructive Uropathy, Tubulointerstitial Disease & Hematuria
11 Chapter 10: Neurology (4% of Exam)
10.1 Acute Ischemic Stroke: Syndromes & Reperfusion 10.2 Transient Ischemic Attack, Secondary Prevention & Hemorrhagic Stroke 10.3 Headache & Facial Pain 10.4 Seizures, Epilepsy & Movement Disorders 10.5 Multiple Sclerosis & Neuromuscular Junction Disorders 10.6 Motor Neuron Disease & Acute Peripheral Neuropathy 10.7 Cranial Neuropathies & Neuro-Ophthalmology 10.8 Peripheral Neuropathies, CNS Tumors & Other Neurologic Disorders
12 Chapter 11: Psychiatry & Behavioral Health (4% of Exam)
11.1 Major Depressive Disorder & Medical Mimics 11.2 Antidepressant Pharmacotherapy & Treatment-Resistant Depression 11.3 Bipolar Disorder, Mood Stabilizers & Lithium Toxicity 11.4 Anxiety, Stress-Related & Obsessive-Compulsive Disorders 11.5 Alcohol Use Disorder & Withdrawal 11.6 Pharmacotherapy for Alcohol & Opioid Use Disorder 11.7 Toxidromes, Psychiatric Emergencies & Suicide Risk Assessment 11.8 Psychotic, Somatic Symptom, Factitious & Personality Disorders 11.9 Eating Disorders, Sleep Disorders & Sexual Health
13 Chapter 12: Dermatology (3% of Exam)
12.1 Dermatitis, Papulosquamous & Inflammatory Dermatoses 12.2 Acne, Rosacea & Cutaneous Infections 12.3 Herpes Zoster & Autoimmune Blistering Diseases 12.4 Nodules, Tumors & Cutaneous Oncology 12.5 Dermatologic Emergencies & Severe Cutaneous Adverse Reactions 12.6 Pigment Disorders, Alopecia, Nail Disease & Photosensitivity 12.7 Vascular Dermatoses, Environmental Injury & Cutaneous Signs of Systemic Disease
14 Chapter 13: Obstetrics & Gynecology / Women's Health (3% of Exam)
13.1 Contraception, Preconception Care & Teratogenicity 13.2 Hypertensive Disorders of Pregnancy & Gestational Diabetes 13.3 Thyroid Disease & Venous Thromboembolism in Pregnancy 13.4 Menopause & Menopausal Hormone Therapy 13.5 Abnormal Uterine Bleeding, Endometrial Disease & Gynecologic Cancer Screening 13.6 Breast Disorders & Diseases of the Vulva and Vagina 13.7 Menstrual Disorders, Fibroids, Endometriosis & Early Pregnancy Complications
15 Chapter 14: Geriatric Syndromes (3% of Exam)
14.1 Comprehensive Geriatric Assessment & Frailty 14.2 Falls, Gait Assessment & Polypharmacy 14.3 Urinary Incontinence & Pressure Injuries in Older Adults 14.4 Mild Cognitive Impairment, Dementia & Its Subtypes 14.5 Delirium & the Pharmacotherapy of Cognitive Disorders 14.6 Palliative Care, Hospice & Advance Care Planning 14.7 Chronic Wounds, Nutrition, Swallowing, Constipation & Hip Fracture 14.8 Sensory Impairment, Dizziness, Elder Mistreatment & Care Settings
16 Chapter 15: Allergy & Immunology (2% of Exam)
15.1 Anaphylaxis: Recognition & Emergency Management 15.2 Urticaria & Angioedema 15.3 Drug Allergy, Desensitization & Adult Immunodeficiency 15.4 Food Allergy, Insect Venom Hypersensitivity, Serum Sickness & Contrast Reactions 15.5 Rhinitis, Conjunctivitis, Eosinophilic & Mast Cell Disorders
17 Chapter 16: Preventive Medicine, Immunization & Clinical Epidemiology
16.1 The USPSTF Framework & Evidence-Based Cancer Screening 16.2 Cardiovascular & Metabolic Screening and Primary Prevention 16.3 Adult Immunization & Vaccines in Special Populations 16.4 Clinical Epidemiology, Biostatistics & Study Design
18 Chapter 17: Miscellaneous - Ethics, Patient Safety & Quality Improvement (2% of Exam)
17.1 Principles of Bioethics & Decisional Capacity 17.2 Informed Consent, Treatment Refusal & Special Scenarios 17.3 Surrogate Decision-Making, Advance Directives & Confidentiality 17.4 Patient Safety Science, Medical Error & Diagnostic Reasoning 17.5 Quality Improvement Methods, Health Disparities & Health Equity
19 Chapter 18: Perioperative Medicine & Medical Consultation
18.1 Preoperative Cardiovascular Risk Assessment 18.2 Preoperative Pulmonary Risk & Perioperative Medication Management 18.3 Perioperative Anticoagulation, Bridging & Postoperative Complications
20 Chapter 19: Ophthalmology (1% of Exam)
19.1 The Acute Red Eye & Ophthalmic Emergencies 19.2 Painless Vision Loss & Chronic Ophthalmic Disease 19.3 Uveitis, Scleritis & Orbital Disease
21 Chapter 20: Otolaryngology & Dental Medicine (1% of Exam)
20.1 Dizziness, Vertigo & Epistaxis 20.2 Ear Disorders, Hearing Loss & Upper Respiratory Infections 20.3 Oral Cavity, Salivary Gland, Laryngeal & Taste and Smell Disorders
5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy
Key Takeaways Explain This Topic AI
Obstructive airway disease is a 2.5% blueprint subsection listing general asthma and chronic bronchitis with emphysema.
Diagnosis of COPD requires a post-bronchodilator ratio of forced expiratory volume in one second to forced vital capacity below 0.70.
Spirometric grade reflects the degree of airflow limitation, whereas the treatment group is assigned from symptom scores and exacerbation history.
Blood eosinophil count guides whether an inhaled corticosteroid should be added to long-acting bronchodilator therapy.
Alpha-1 antitrypsin testing is recommended in all patients with COPD, particularly with early onset, a minimal smoking history or basilar-predominant emphysema.
Last updated: August 2026
Obstructive airway disorders represent one of the highest-yield domains on the ABIM Internal Medicine certification examination. Mastery requires a deep understanding of spirometric interpretation, the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, mortality-reducing interventions, exacerbation triage and pharmacotherapy, the 2024 Global Initiative for Asthma (GINA) Track 1 Single Maintenance and Reliever Therapy (SMART) paradigm, and the targeted application of biologic agents.
1. Chronic Obstructive Pulmonary Disease (COPD): Diagnosis & Pathophysiology
COPD is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production) resulting from airway abnormalities (bronchitis, bronchiolitis) and/or alveolar abnormalities (emphysema) that cause persistent, often progressive airflow limitation.
Diagnostic Spirometry
Gold Standard Diagnostic Criterion: A post-bronchodilator FEV1/FVC ratio < 0.70 (fixed ratio) measured via spirometry 15–30 minutes after inhaling 400 mcg of albuterol confirms persistent airflow limitation.
Unlike asthma, the airflow obstruction in COPD is typically irreversible or only partially reversible.
Alpha-1 Antitrypsin (AAT) Deficiency Screening: The WHO and GOLD guidelines recommend screening all patients with COPD at least once with a serum AAT level. Test specifically in patients who present at age <45 years, non-smokers, or those with basilar-predominant panacinar emphysema. Normal genotype is PiMM; severe deficiency is PiZZ (serum AAT <11 µmol/L or <57 mg/dL). Intravenous human alpha-1 proteinase inhibitor augmentation slows emphysema progression.
Pathophysiologic Mechanisms
Small Airway Disease (Obstructive Bronchiolitis): Chronic inflammation of small conducting airways (<2 mm diameter), goblet cell hyperplasia, mucus hypersecretion, peribronchiolar fibrosis, and luminal plugging.
Emphysema: Destruction of gas-exchanging respiratory bronchioles and alveolar walls without obvious fibrosis, mediated by an imbalance between neutrophil elastases/proteases and antiproteases (e.g., alpha-1 antitrypsin), combined with oxidative stress from cigarette smoke or biomass exposure.
Centriacinar (Centrilobular) Emphysema: Involves the proximal respiratory bronchioles; strongly associated with cigarette smoking; predominant in the upper lung zones .
Panacinar (Panlobular) Emphysema: Uniform destruction of the entire acinus from respiratory bronchiole to alveoli; characteristic of Alpha-1 Antitrypsin deficiency ; predominant in the lower lung zones .
Dynamic Hyperinflation & Air Trapping: Loss of elastic recoil and premature expiratory airway collapse lead to incomplete lung emptying during expiration, resulting in elevated functional residual capacity (FRC), elevated residual volume (RV), flattened diaphragms, increased work of breathing, and exertional dyspnea.
2. GOLD 2024 Classification & Staging
COPD classification combines spirometric severity (GOLD Grades 1–4) with symptom burden and exacerbation risk (Refined ABE Assessment).
Spirometric Classification of Airflow Limitation (Post-Bronchodilator FEV1)
All categories require a post-bronchodilator FEV1/FVC < 0.70:
- GOLD Grade Severity Post-Bronchodilator FEV1 (% Predicted)
- GOLD 1 Mild FEV1 >= 80% predicted
- GOLD 2 Moderate 50% <= FEV1 < 80% predicted
- GOLD 3 Severe 30% <= FEV1 < 50% predicted
- GOLD 4 Very Severe FEV1 < 30% predicted
- The 2024 Refined GOLD ABE Assessment Framework
In the updated GOLD framework, historical Groups C and D are merged into Group E to emphasize the clinical importance and therapeutic urgency of exacerbation prevention.
Symptom Assessment Tools:
mMRC (Modified Medical Research Council) Dyspnea Scale: Grade 0 (dyspneic only on strenuous exercise) to Grade 4 (too dyspneic to leave house or breathless dressing). Cutoff: <2 vs. >=2 .
CAT (COPD Assessment Test): Multi-item health status questionnaire (score 0–40). Cutoff: <10 vs. >=10 .
Exacerbation History Classification:
Low Risk: 0 or 1 moderate exacerbation in the past 12 months (not leading to hospital admission).
High Risk (Group E): >=2 moderate exacerbations OR >=1 exacerbation requiring hospital admission in the past 12 months.
Loading diagram... GOLD 2024 Refined ABE Assessment and Initial Pharmacotherapy Algorithm
GOLD 2024 Initial Pharmacotherapy Regimens
Group A (Low Symptoms, Low Exacerbation Risk):
Initial Regimen: A single bronchodilator — either short-acting (SABA or SAMA PRN) or long-acting (LABA or LAMA).
Group B (High Symptoms, Low Exacerbation Risk):
Initial Regimen: LABA + LAMA combination (e.g., Tiotropium/Olodaterol, Umeclidinium/Vilanterol, Glycopyrrolate/Formoterol). Dual long-acting bronchodilation is superior to monotherapy for symptom relief, lung function improvement, and exercise tolerance.
Group E (High Exacerbation Risk, regardless of symptom score):
Initial Regimen: LABA + LAMA combination .
Role of Inhaled Corticosteroids (ICS): Add an ICS (initiating LABA + LAMA + ICS triple therapy ) as first-line if blood eosinophils are >= 300 cells/mcL .
If blood eosinophils are 100–299 cells/mcL , initiate LABA + LAMA; add ICS if recurrent exacerbations persist despite dual bronchodilation.
If blood eosinophils are < 100 cells/mcL , ICS therapy offers minimal benefit and significantly increases the risk of pneumonia; avoid ICS.
Follow-up Escalation & Targeted Second-Line Agents
Roflumilast (PDE4 Inhibitor): 500 mcg PO daily. Indicated as add-on therapy for patients with FEV1 < 50% predicted, chronic bronchitis phenotype (frequent cough and sputum), and >=1 hospital admission for exacerbation in the past year on optimal inhaled therapy. Side effects: weight loss, nausea, diarrhea, neuropsychiatric symptoms (depression, insomnia).
Macrolide Maintenance (Azithromycin): Azithromycin 250 mg daily or 500 mg three times weekly for 1 year in former smokers with persistent exacerbations on triple therapy. Reduces exacerbation frequency. Pre-treatment evaluation: baseline 12-lead ECG (confirm QTc < 450 ms in men, < 470 ms in women), audiometry (risk of sensorineural ototoxicity), and sputum mycobacterial culture (to avoid inducing macrolide resistance in occult Mycobacterium avium complex).